Advancing Boundaries of Combination Immunotherapy to Fight Cancer

KAHR is developing an innovative and novel drug platform of immunotherapeutic bi-functional fusion proteins that harness the human immune system to target multiple cancer indications.

The Company's lead asset is a first-in-class CD47x41BB targeting compound, activating both innate and adaptive immunity with potential to fight solid tumors.

KAHR’s technology platform is based on multi-functional immuno-recruitment proteins (MIRP) that utilize overexpression of checkpoint antigens on cancer cells to selectively target and bind to the tumor. MIRPs bridge cancer cells to immune cells to produce a targeted synergistic effect by combining immune checkpoint inhibition with localized immune cell activation, unmasking cancer cell camouflage to enable innate immune response, while recruiting the adaptive immune system to bind and selectively kill the cancer cells.